These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 34546844)

  • 1. A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly.
    Leleu X; Chari A; Richard S; Khurana M; Yusuf A; Usmani SZ
    Expert Rev Hematol; 2021 Dec; 14(12):1049-1058. PubMed ID: 34546844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of weekly carfilzomib (70 mg/m
    Leleu X; Beksac M; Chou T; Dimopoulos M; Yoon SS; Prince HM; Pour L; Shelekhova T; Chari A; Khurana M; Zhang J; Obreja M; Qi M; Oriol A; Siegel D
    Leuk Lymphoma; 2021 Feb; 62(2):358-367. PubMed ID: 33112184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
    Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
    Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.
    Richard S; Jagannath S; Cho HJ; Parekh S; Madduri D; Richter J; Chari A
    Expert Rev Hematol; 2021 Jan; 14(1):31-45. PubMed ID: 33331794
    [No Abstract]   [Full Text] [Related]  

  • 5. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
    Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
    Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carfilzomib 56 mg/m
    Weisel K; Nooka AK; Terpos E; Spencer A; Goldschmidt H; Dirnberger F; DeCosta L; Yusuf A; Kumar S
    Leuk Lymphoma; 2022 Aug; 63(8):1887-1896. PubMed ID: 35289710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
    Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly (70 mg/m
    Moreau P; Stewart KA; Dimopoulos M; Siegel D; Facon T; Berenson J; Raje N; Berdeja JG; Orlowski RZ; Yang H; Ma H; Klippel Z; Zahlten-Kumeli A; Mezzi K; Iskander K; Mateos MV
    Cancer Med; 2020 May; 9(9):2989-2996. PubMed ID: 32108443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.
    Weisel K; Dimopoulos MA; Beksac M; Leleu X; Richter J; Heeg B; Patel S; Majer I; McFadden I; Mikhael J
    Leuk Lymphoma; 2024 Apr; 65(4):481-492. PubMed ID: 38345269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.
    Dimopoulos MA; Moreau P; Iida S; Huang SY; Takezako N; Chng WJ; Zahlten-Kumeli A; Sersch MA; Li J; Huang M; Lee JH
    Int J Hematol; 2019 Oct; 110(4):466-473. PubMed ID: 31388932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma.
    Touzeau C; Antier C; Moreau P
    Future Oncol; 2021 Mar; 17(9):993-998. PubMed ID: 33289427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study).
    Abe Y; Kubonishi S; Ri M; Iino M; Sunami K; Ito T; Fukaya M; Kitano T; Ikeda S; Ota S; Kuroi T; Iriyama N; Jo T; Adachi M; Akahane D; Kai T; Kohara Y; Kadowaki N; Katayama T
    Future Oncol; 2024; 20(17):1191-1205. PubMed ID: 38420911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial.
    Suzuki K; Min CK; Kim K; Lee JJ; Shibayama H; Ko PS; Huang SY; Li SS; Ding B; Khurana M; Iida S
    Int J Hematol; 2021 Dec; 114(6):653-663. PubMed ID: 34410635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
    Dimopoulos MA; Coriu D; Delimpasi S; Špička I; Upchurch T; Fang B; Talpur R; Faber E; Beksac M; Leleu X
    Blood Adv; 2024 Oct; 8(19):5012-5021. PubMed ID: 39024542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma.
    Schroeder MA; Fiala MA; Huselton E; Cardone MH; Jaeger S; Jean SR; Shea K; Ghobadi A; Wildes T; Stockerl-Goldstein KE; Vij R
    Clin Cancer Res; 2019 Jul; 25(13):3776-3783. PubMed ID: 30952640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.
    Masood A; Iqbal Q; Ehsan H; Davis JA; Hansen DK; Hashmi H
    Ann Hematol; 2022 Dec; 101(12):2601-2610. PubMed ID: 36214853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
    Landgren O; Weisel K; Rosinol L; Touzeau C; Turgut M; Hajek R; Mollee P; Kim JS; Shu N; Hu X; Li C; Usmani SZ
    Br J Haematol; 2022 Sep; 198(6):988-993. PubMed ID: 35608261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study.
    Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Shu X; Li C; Dimopoulos M
    Blood Adv; 2023 Jul; 7(14):3739-3748. PubMed ID: 37163358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
    Berenson JR; Cartmell A; Bessudo A; Lyons RM; Harb W; Tzachanis D; Agajanian R; Boccia R; Coleman M; Moss RA; Rifkin RM; Patel P; Dixon S; Ou Y; Anderl J; Aggarwal S; Berdeja JG
    Blood; 2016 Jun; 127(26):3360-8. PubMed ID: 27207788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.